Profile data is unavailable for this security.
About the company
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
- Revenue in USD (TTM)629.18m
- Net income in USD53.87m
- Incorporated1959
- Employees1.55k
- LocationTaro Pharmaceutical Industries Ltd14 Hakitor Street,PO Box 10347HAIFA 2624761IsraelISR
- Phone+972 48475700
- Fax+972 48727165
- Websitehttps://www.taro.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xencor Inc | 162.18m | -133.36m | 1.47bn | 280.00 | -- | 2.39 | -- | 9.04 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.48bn | 124.00 | -- | 2.23 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Dynavax Technologies Corp | 236.15m | 9.22m | 1.50bn | 408.00 | 229.43 | 2.42 | 109.69 | 6.35 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Neumora Therapeutics Inc | 0.00 | -254.02m | 1.51bn | 120.00 | -- | 3.55 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.54bn | 33.00 | -- | 10.29 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.54bn | 154.00 | -- | 19.62 | -- | 27.89 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 597.40m | -15.51m | 1.54bn | 652.00 | -- | 1.66 | 22.17 | 2.58 | -0.2843 | -0.2843 | 10.86 | 16.90 | 0.3859 | 0.922 | 4.10 | 916,259.20 | -1.00 | 4.95 | -1.51 | 6.41 | 87.17 | 88.61 | -2.60 | 12.84 | 1.49 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.56bn | 58.00 | 16.62 | 1.93 | 11.83 | 13.21 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Arcus Biosciences Inc | 237.00m | -231.00m | 1.57bn | 577.00 | -- | 2.22 | -- | 6.62 | -3.10 | -3.10 | 3.07 | 7.78 | 0.1861 | -- | 6.24 | 410,745.20 | -18.14 | -15.85 | -21.35 | -18.25 | -- | -- | -97.47 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.58bn | 1.60k | -- | 0.4402 | -- | 2.12 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Taro Pharmaceutical Industries Ltd | 629.18m | 53.87m | 1.60bn | 1.55k | 29.67 | 0.8914 | 18.81 | 2.54 | 1.43 | 1.43 | 16.74 | 47.70 | 0.2928 | 1.50 | 3.31 | -- | 2.51 | -0.166 | 3.03 | -0.2023 | 48.47 | 52.85 | 8.56 | -0.6294 | 3.04 | -- | 0.00 | -- | 9.81 | -1.25 | 111.70 | -28.17 | 12.06 | -- |
| Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 1.62bn | 1.22k | -- | 1.51 | -- | 7.75 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 1.67bn | 111.00 | -- | 3.88 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.67bn | 92.00 | -- | 3.12 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.68bn | 246.00 | 12.80 | 3.27 | 10.39 | 2.73 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.68bn | 142.00 | -- | 3.33 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
Data as of May 22 2024. Currency figures normalised to Taro Pharmaceutical Industries Ltd's reporting currency: US Dollar USD
9.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Krensavage Asset Management LLCas of 31 Mar 2024 | 647.87k | 1.72% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 571.10k | 1.52% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 548.55k | 1.46% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 519.68k | 1.38% |
| Brandes Investment Partners LPas of 31 Mar 2024 | 283.92k | 0.76% |
| Eversept Partners LPas of 31 Mar 2024 | 263.54k | 0.70% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 231.00k | 0.62% |
| Columbia Management Investment Advisers LLCas of 31 Mar 2024 | 227.64k | 0.61% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 172.83k | 0.46% |
| HSBC Bank Plc (Broker)as of 31 Mar 2024 | 95.32k | 0.25% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
